Search

Your search keyword '"Langley, Ruth E."' showing total 314 results
Start Over Author "Langley, Ruth E."
314 results on '"Langley, Ruth E."'

52. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Author

Cunningham, David, Van de Velde, Cornelis J.H., Nicolson, Marianne, Scarffe, J. Howard, Allum, William H., Stenning, Sally P., Thompson, Jeremy N., Lofts, Fiona J., Falk, Stephen J., Iveson, Timothy J., Smith, David B., Langley, Ruth E., Verma, Monica, Weeden, Simon, and Yu Jo Chua

Subjects
Gastrointestinal diseases -- Drug therapy, Chemotherapy -- Health aspects, Epirubicin -- Dosage and administration, Cisplatin -- Dosage and administration, Cancer -- Chemotherapy, Cancer -- Health aspects
Abstract

A study aims to determine whether a regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) given before and after radical surgery improves outcomes among patients with potentially curable gastric cancer. Results indicate that a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival.

Published
2006

55. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03)

Author

Athauda, Avani, primary, Nankivell, Matthew, additional, Langley, Ruth E., additional, Alderson, Derek, additional, Allum, William, additional, Grabsch, Heike I., additional, Starling, Naureen, additional, Chau, Ian, additional, and Cunningham, David, additional

Published
2020
Full Text
View/download PDF

56. Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial

Author

Davarzani, Naser, primary, Hewitt, Lindsay C, additional, Hale, Matthew D, additional, Melotte, Veerle, additional, Nankivell, Matthew, additional, Hutchins, Gordon G A, additional, Cunningham, David, additional, Allum, William H, additional, Langley, Ruth E, additional, Jolani, Shahab, additional, and Grabsch, Heike I, additional

Published
2020
Full Text
View/download PDF

58. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer

Author

Pietrantonio, Filippo, primary, Miceli, Rosalba, additional, Raimondi, Alessandra, additional, Kim, Young Woo, additional, Kang, Won Ki, additional, Langley, Ruth E., additional, Choi, Yoon Young, additional, Kim, Kyoung-Mee, additional, Nankivell, Matthew Guy, additional, Morano, Federica, additional, Wotherspoon, Andrew, additional, Valeri, Nicola, additional, Kook, Myeong-Cherl, additional, An, Ji Yeong, additional, Grabsch, Heike I., additional, Fucà, Giovanni, additional, Noh, Sung Hoon, additional, Sohn, Tae Sung, additional, Kim, Sung, additional, Di Bartolomeo, Maria, additional, Cunningham, David, additional, Lee, Jeeyun, additional, Cheong, Jae-Ho, additional, and Smyth, Elizabeth Catherine, additional

Published
2019
Full Text
View/download PDF

59. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial

Author

Sundar, Raghav, primary, Ng, Alvin, additional, Zouridis, Hermioni, additional, Padmanabhan, Nisha, additional, Sheng, Taotao, additional, Zhang, Shenli, additional, Lee, Ming Hui, additional, Ooi, Wen Fong, additional, Qamra, Aditi, additional, Inam, Imran, additional, Hewitt, Lindsay C., additional, So, Jimmy Bok-Yan, additional, Koh, Vivien, additional, Nankivell, Matthew G., additional, Langley, Ruth E., additional, Allum, William H., additional, Cunningham, David, additional, Rozen, Steven G., additional, Yong, Wei Peng, additional, Grabsch, Heike I., additional, and Tan, Patrick, additional

Published
2019
Full Text
View/download PDF

62. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Author

Parker, Christopher C., James, Nicholas D., Brawley, Christopher D., Clarke, Noel W., Hoyle, Alex P., Ali, Adnan, Ritchie, Alastair W.S., Attard, Gerhardt, Chowdhury, Simon, Cross, William, Dearnaley, David P., Gillessen, Silke, Gilson, Clare, Jones, Robert J., Langley, Ruth E., Malik, Zafar I., Mason, Malcolm D., Matheson, David, Millman, Robin, Russell, J. Martin, Thalmann, George N., Amos, Claire L., Alonzi, Roberto, Bahl, Amit, Birtle, Alison, Din, Omar, Douis, Hassan, Eswar, Chinnamani, Gale, Joanna, Gannon, Melissa R., Jonnada, Sai, Khaksar, Sara, Lester, Jason F., O'Sullivan, Joe M., Parikh, Omi A., Pedley, Ian D., Pudney, Delia M., Sheehan, Denise J., Srihari, Narayanan Nair, Tran, Anna T.H., Parmar, Mahesh K.B., and Sydes, Matthew R.

Subjects
Oncology, Male, medicine.medical_specialty, Urology, medicine.medical_treatment, MEDLINE, Antineoplastic Agents, 610 Medicine & health, Newly diagnosed, Docetaxel, Article, Disease-Free Survival, Gonadotropin-Releasing Hormone, Prostate cancer, Internal medicine, Medicine, Humans, Neoplasm Metastasis, Docetaxel/therapeutic use, Aged, Gonadotropin-Releasing Hormone/agonists, Radiotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Androgen Antagonists, Antineoplastic Agents/therapeutic use, Prostatic Neoplasms, Standard of Care, Middle Aged, medicine.disease, Survival Analysis, Radiotherapy/adverse effects, Radiation therapy, Treatment Outcome, Lymph Nodes/pathology, Prostatic Neoplasms/drug therapy, Lymph Nodes, business, Orchiectomy
Abstract

BACKGROUND Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy. METHODS We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and the UK. Eligible patients had newly diagnosed metastatic prostate cancer. We randomly allocated patients open-label in a 1:1 ratio to standard of care (control group) or standard of care and radiotherapy (radiotherapy group). Randomisation was stratified by hospital, age at randomisation, nodal involvement, WHO performance status, planned androgen deprivation therapy, planned docetaxel use (from December, 2015), and regular aspirin or non-steroidal anti-inflammatory drug use. Standard of care was lifelong androgen deprivation therapy, with up-front docetaxel permitted from December, 2015. Men allocated radiotherapy received either a daily (55 Gy in 20 fractions over 4 weeks) or weekly (36 Gy in six fractions over 6 weeks) schedule that was nominated before randomisation. The primary outcome was overall survival, measured as the number of deaths; this analysis had 90% power with a one-sided α of 2·5% for a hazard ratio (HR) of 0·75. Secondary outcomes were failure-free survival, progression-free survival, metastatic progression-free survival, prostate cancer-specific survival, and symptomatic local event-free survival. Analyses used Cox proportional hazards and flexible parametric models, adjusted for stratification factors. The primary outcome analysis was by intention to treat. Two prespecified subgroup analyses tested the effects of prostate radiotherapy by baseline metastatic burden and radiotherapy schedule. This trial is registered with ClinicalTrials.gov, number NCT00268476. FINDINGS Between Jan 22, 2013, and Sept 2, 2016, 2061 men underwent randomisation, 1029 were allocated the control and 1032 radiotherapy. Allocated groups were balanced, with a median age of 68 years (IQR 63-73) and median amount of prostate-specific antigen of 97 ng/mL (33-315). 367 (18%) patients received early docetaxel. 1082 (52%) participants nominated the daily radiotherapy schedule before randomisation and 979 (48%) the weekly schedule. 819 (40%) men had a low metastatic burden, 1120 (54%) had a high metastatic burden, and the metastatic burden was unknown for 122 (6%). Radiotherapy improved failure-free survival (HR 0·76, 95% CI 0·68-0·84; p

Published
2018

64. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours

Author

Coyle, Christopher, Cafferty, Fay H., Rowley, Samuel, MacKenzie, Mairead, Berkman, Lindy, Gupta, Sudeep, Pramesh, C S, Gilbert, Duncan, Kynaston, Howard, Cameron, David, Wilson, Richard H., Ring, Alistair, and Langley, Ruth E.

Subjects
Male, Peptic Ulcer, Esophageal Neoplasms, Gastro-oesophageal cancer, India, Breast Neoplasms, Article, Disease-Free Survival, Drug Hypersensitivity, Macular Degeneration, Tinnitus, Breast cancer, SDG 3 - Good Health and Well-being, Double-Blind Method, Stomach Neoplasms, Neoplasms, Humans, Pharmacology (medical), Longitudinal Studies, Medicine(all), Randomised controlled trial, Prostate cancer, Aspirin, Anti-Inflammatory Agents, Non-Steroidal, Prostatic Neoplasms, Colorectal cancer, United Kingdom, Survival Rate, Chemotherapy, Adjuvant, Female, Neoplasm Recurrence, Local, Colorectal Neoplasms, Gastrointestinal Hemorrhage, Intracranial Hemorrhages
Abstract

Background\ud \ud There is a considerable body of pre-clinical, epidemiological and randomised data to support the hypothesis that aspirin has the potential to be an effective adjuvant cancer therapy.\ud \ud Methods\ud \ud Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four parallel cohorts. Patients who have undergone potentially curative treatment for breast (n = 3100), colorectal (n = 2600), gastro-oesophageal (n = 2100) or prostate cancer (n = 2120) are registered into four tumour specific cohorts. All cohorts recruit in the United Kingdom, with the breast and gastro-oesophageal cohort also recruiting in India. Eligible participants first undertake an active run-in period where 100 mg aspirin is taken daily for approximately eight weeks. Participants who are able to adhere and tolerate aspirin then undergo a double-blind randomisation and are allocated in a 1:1:1 ratio to either 100 mg aspirin, 300 mg aspirin or a matched placebo to be taken daily for at least five years. Those participants ≥ 75 years old are only randomised to 100 mg aspirin or placebo due to increased toxicity risk.\ud \ud Results\ud \ud The primary outcome measures are invasive disease-free survival for the breast cohort, disease-free survival for the colorectal cohort, overall survival for the gastro-oesophageal cohort, and biochemical recurrence-free survival for the prostate cohort, with a co-primary outcome of overall survival across all cohorts. Secondary outcomes include adherence, toxicity including serious haemorrhage, cardiovascular events and some cohort specific measures.\ud \ud Conclusions\ud \ud The Add-Aspirin trial investigates whether regular aspirin use after standard therapy prevents recurrence and prolongs survival in participants with four non-metastatic common solid tumours.

Published
2016

65. Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma

Author

Smyth, Elizabeth C., primary, Rowley, Samuel, additional, Cafferty, Fay H., additional, Allum, William, additional, Grabsch, Heike I., additional, Stenning, Sally, additional, Wotherspoon, Andrew, additional, Alderson, Derek, additional, Crosby, Tom, additional, Mansoor, Was, additional, Waters, Justin S., additional, Neville-Webbe, Helen, additional, Darby, Suzanne, additional, Dent, Jo, additional, Seymour, Matthew, additional, Thompson, Joyce, additional, Sothi, Sharmila, additional, Blazeby, Jane, additional, Langley, Ruth E., additional, and Cunningham, David, additional

Published
2019
Full Text
View/download PDF

66. Targeted next-generation sequencing (tNGS) of metastatic castrate-sensitive prostate cancer (M1 CSPC): A pilot molecular analysis in the STAMPEDE multi-center clinical trial.

Author

Gilson, Clare, primary, Ingleby, Fiona, additional, Gilbert, Duncan C, additional, Parry, Marina, additional, Atako, Nafisah B, additional, Mason, Malcolm David, additional, Malik, Zafar, additional, Langley, Ruth E, additional, Simmons, Andrew, additional, Loehr, Andrea, additional, Clarke, Noel, additional, James, Nicholas, additional, Parmar, Mahesh K B, additional, Sydes, Matthew Robert, additional, Attard, Gerhardt, additional, and Chowdhury, Simon, additional

Published
2019
Full Text
View/download PDF

67. Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03).

Author

Athauda, Avani, primary, Nankivell, Matthew Guy, additional, Langley, Ruth E, additional, Alderson, Derek, additional, Allum, William H., additional, Grabsch, Heike I, additional, Chau, Ian, additional, Starling, Naureen, additional, Falk, Stephen, additional, Crellin, Adrian, additional, Mansoor, Wasat, additional, Coxon, Fareeda, additional, Darby, Suzanne, additional, Thompson, Joyce, additional, Cummins, Sebastian J., additional, Beaumont, Erica, additional, West, Nicholas, additional, Langer, Rupert, additional, Pritchard, Susan, additional, and Cunningham, David, additional

Published
2019
Full Text
View/download PDF

68. DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.

Author

Sundar, Raghav, primary, Ng, Alvin, additional, Zouridis, Hermioni, additional, Sheng, Taotao, additional, Zhang, Shenli, additional, Lee, Ming Hui, additional, Padmanabhan, Nisha, additional, Ooi, Wen Fong, additional, Qamra, Aditi, additional, Nankivell, Matthew Guy, additional, Langley, Ruth E., additional, Allum, William H., additional, Cunningham, David, additional, Grabsch, Heike I, additional, and Tan, Patrick, additional

Published
2019
Full Text
View/download PDF

69. MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).

Author

Pietrantonio, Filippo, primary, Raimondi, Alessandra, additional, Choi, Yoon Young, additional, Kang, WonKi, additional, Langley, Ruth E., additional, Kim, Young Woo, additional, Kim, Kyoung-Mee, additional, Nankivell, Matthew Guy, additional, Perrone, Federica, additional, Kook, Myeong-Cherl, additional, An, Ji Yeong, additional, Grabsch, Heike I., additional, Morano, Federica, additional, Cheong, Jae-Ho, additional, Noh, Sung Hoon, additional, Lee, Jeeyun, additional, Cunningham, David, additional, Di Bartolomeo, Maria, additional, Fucà, Giovanni, additional, and Smyth, Elizabeth Catherine, additional

Published
2019
Full Text
View/download PDF

72. Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial

Author

Davarzani, Nasser, primary, Hutchins, Gordon G A, additional, West, Nicholas P, additional, Hewitt, Lindsay C, additional, Nankivell, Matthew, additional, Cunningham, David, additional, Allum, William H, additional, Smyth, Elizabeth, additional, Valeri, Nicola, additional, Langley, Ruth E, additional, and Grabsch, Heike I, additional

Published
2018
Full Text
View/download PDF

74. A randomised comparison evaluating changes in bone mineral density in advanced prostate cancer: luteinising hormone-releasing hormone agonists versus transdermal oestradiol

Author

Langley, Ruth E., Kynaston, Howard, Alhasso, Abdulla A., Duong, Trinh, Paez, Edgar M., Jovic, Gordana, Scrase, Christopher D., Robertson, Andrew, Cafferty, Fay, Welland, Andrew, Carpenter, Robin, Honeyfield, Lesley, Abel, Richard L., Stone, Michael D., Parmar, Mahesh K.B., Abel, Paul D., and Cancer Research UK

Subjects
Science & Technology, Prostate cancer, CALCIUM INTAKE, CARCINOMA, Urology, MEN, 1103 Clinical Sciences, Urology & Nephrology, CONTROLLED-TRIAL, FRACTURE, METASTASES, Androgen-deprivation therapy, ZOLEDRONIC ACID, Bone mineral density, Transdermal oestradiol, LHRH agonist, Life Sciences & Biomedicine, METAANALYSIS, PARENTERAL ESTROGEN
Abstract

BackgroundLuteinising hormone-releasing hormone agonists (LHRHa), used as androgen deprivation therapy (ADT) in prostate cancer (PCa) management, reduce serum oestradiol as well as testosterone, causing bone mineral density (BMD) loss. Transdermal oestradiol is a potential alternative to LHRHa.ObjectiveTo compare BMD change in men receiving either LHRHa or oestradiol patches (OP).Design, setting, and participantsMen with locally advanced or metastatic PCa participating in the randomised UK Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) trial (allocation ratio of 1:2 for LHRHa:OP, 2006–2011; 1:1, thereafter) were recruited into a BMD study (2006–2012). Dual-energy x-ray absorptiometry scans were performed at baseline, 1 yr, and 2 yr.InterventionsLHRHa as per local practice, OP (FemSeven 100μg/24h patches).Outcome measurements and statistical analysisThe primary outcome was 1-yr change in lumbar spine (LS) BMD from baseline compared between randomised arms using analysis of covariance.Results and limitationsA total of 74 eligible men (LHRHa 28, OP 46) participated from seven centres. Baseline clinical characteristics and 3-mo castration rates (testosterone ≤1.7 nmol/l, LHRHa 96% [26 of 27], OP 96% [43 of 45]) were similar between arms. Mean 1-yr change in LS BMD was −0.021g/cm3 for patients randomised to the LHRHa arm (mean percentage change −1.4%) and +0.069g/cm3 for the OP arm (+6.0%; p

Published
2015

75. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial

Author

Alderson, Derek, primary, Cunningham, David, additional, Nankivell, Matthew, additional, Blazeby, Jane M, additional, Griffin, S Michael, additional, Crellin, Adrian, additional, Grabsch, Heike I, additional, Langer, Rupert, additional, Pritchard, Susan, additional, Okines, Alicia, additional, Krysztopik, Richard, additional, Coxon, Fareeda, additional, Thompson, Joyce, additional, Falk, Stephen, additional, Robb, Clare, additional, Stenning, Sally, additional, and Langley, Ruth E, additional

Published
2017
Full Text
View/download PDF

76. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols

Author

Parmar, Mahesh KB, primary, Sydes, Matthew R, additional, Cafferty, Fay H, additional, Choodari-Oskooei, Babak, additional, Langley, Ruth E, additional, Brown, Louise, additional, Phillips, Patrick PJ, additional, Spears, Melissa R, additional, Rowley, Sam, additional, Kaplan, Richard, additional, James, Nicholas D, additional, Maughan, Timothy, additional, Paton, Nicholas, additional, and Royston, Patrick J, additional

Published
2017
Full Text
View/download PDF

80. How do the QUARTZ trial results inform future research for patients with brain metastases from non-small cell lung cancer?

Author

Nankivell, Matthew, primary, Langley, Ruth E., additional, Barton, Rachael, additional, Faivre-Finn, Corinne, additional, Wilson, Paula, additional, McColl, Elaine, additional, Moore, Barbara, additional, Brisbane, Iona, additional, Ardron, David, additional, Sydes, Benjamin, additional, Stephens, Richard, additional, Parmar, Mahesh, additional, and Mulvenna, Paula, additional

Published
2017
Full Text
View/download PDF

81. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer

Author

Gilbert, Duncan C., primary, Duong, Trinh, additional, Kynaston, Howard G., additional, Alhasso, Abdulla A., additional, Cafferty, Fay H., additional, Rosen, Stuart D., additional, Kanaga-Sundaram, Subramanian, additional, Dixit, Sanjay, additional, Laniado, Marc, additional, Madaan, Sanjeev, additional, Collins, Gerald, additional, Pope, Alvan, additional, Welland, Andrew, additional, Nankivell, Matthew, additional, Wassersug, Richard, additional, Parmar, Mahesh K. B., additional, Langley, Ruth E., additional, and Abel, Paul D., additional

Published
2016
Full Text
View/download PDF

82. Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial

Author

Hale, Matthew D., primary, Nankivell, Matthew, additional, Hutchins, Gordon G., additional, Stenning, Sally P., additional, Langley, Ruth E., additional, Mueller, Wolfram, additional, West, Nicholas P., additional, Wright, Alexander I., additional, Treanor, Darren, additional, Hewitt, Lindsay C., additional, Allum, William H., additional, Cunningham, David, additional, Hayden, Jeremy D., additional, and Grabsch, Heike I., additional

Published
2016
Full Text
View/download PDF

83. Erythema nodosum as a result of estrogen patch therapy for prostate cancer: a case report

Author

Coyle, Christopher, Mangar, Stephen, Abel, Paul, and Langley, Ruth E.

Subjects
Medicine(all), integumentary system, General & Internal Medicine, 1199 Other Medical And Health Sciences, skin and connective tissue diseases
Abstract

© 2015 Coyle et al.Introduction: Erythema nodosum is often associated with a distressing symptomatology, including painful subcutaneous nodules, polyarthropathy, and significant fatigue. Whilst it is a well-documented side-effect of estrogen therapy in females, we describe what we believe to be the first report in the literature of erythema nodosum as a result of estrogen therapy in a male. Case presentation: A 64-year-old Afro-Caribbean man with locally advanced carcinoma of the prostate agreed to participate in a randomized controlled trial comparing estrogen patches with luteinizing hormone-releasing hormone analogs to achieve androgen deprivation, and was allocated to the group receiving estrogen patches. One month later he presented with tender lesions on his shins and painful swelling of his ankles, wrists, and left shoulder. This was followed by progressive severe fatigue that required hospital admission, where he was diagnosed with erythema nodosum by a rheumatologist. Two months after discontinuing the estrogen patches the erythema nodosum, and associated symptoms, had fully resolved, and to date he remains well with no further recurrence. Conclusion: Trial results may establish transdermal estrogen as an alternative to luteinizing hormone-releasing hormone analogs in the management of prostate cancer, and has already been established as a therapy for male to female transsexuals. It is essential to record the toxicity profile of transdermal estrogen in men to ensure accurate safety information. This case report highlights a previously undocumented toxicity of estrogen therapy in men, of which oncologists, urologists, and endocrinologists need to be aware. Rheumatologists and dermatologists should add estrogen therapy to their differential diagnosis of men presenting with erythema nodosum.

Published
2015

84. A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol

Author

Langley, Ruth E., primary, Kynaston, Howard G., additional, Alhasso, Abdulla A., additional, Duong, Trinh, additional, Paez, Edgar M., additional, Jovic, Gordana, additional, Scrase, Christopher D., additional, Robertson, Andrew, additional, Cafferty, Fay, additional, Welland, Andrew, additional, Carpenter, Robin, additional, Honeyfield, Lesley, additional, Abel, Richard L., additional, Stone, Michael, additional, Parmar, Mahesh K.B., additional, and Abel, Paul D., additional

Published
2016
Full Text
View/download PDF

85. Correlation between mismatch repair deficiency (MMRd), microsatellite instability (MSI) and survival in MAGIC.

Author

Smyth, Elizabeth Catherine, primary, Wotherspoon, Andrew, additional, Peckitt, Clare, additional, Nankivell, Matthew Guy, additional, Eltahir, Zakaria, additional, Hulkki Wilson, Sanna, additional, Gonzalez de Castro, David, additional, Okines, Alicia Frances Clare, additional, Langley, Ruth E, additional, and Cunningham, David, additional

Published
2016
Full Text
View/download PDF

87. Clinical evidence for the use of aspirin in the treatment of cancer

Author

Langley, Ruth E

Subjects
mechanisms, treatment, aspirin, cancer, toxicity, Review
Abstract

Although the anti-cancer effects of aspirin were first identified in pre-clinical models four decades ago, a clear role for the drug in either the prevention or treatment of cancer has not been established. Concerns about toxicity, particularly major haemorrhage, and a lack of randomised evidence demonstrating efficacy have limited its use in primary prevention; there was also doubt that a simple aspirin could have a significant therapeutic effect against established malignancy. Three new pieces of evidence: a series of meta-analyses focusing on cancer outcomes from randomised-controlled trials designed to assess the vascular benefits of daily aspirin; the first positive results from a randomised-controlled trial designed to demonstrate that aspirin can prevent cancer in those with a hereditary predisposition; and observational data showing that aspirin use after a cancer diagnosis improves both cancer mortality and overall survival; have led to a re-evaluation of aspirin as a potential anti-cancer agent both for the prevention and treatment of cancer.

Published
2013

88. Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).

Author

Alderson, Derek, primary, Langley, Ruth E, additional, Nankivell, Matthew Guy, additional, Blazeby, Jane M., additional, Griffin, Michael, additional, Crellin, Adrian, additional, Grabsch, Heike I., additional, Okines, Alicia Frances Clare, additional, Goldstein, Cindy, additional, Falk, Stephen, additional, Thompson, Joyce, additional, Krysztopik, Richard, additional, Coxon, Fareeda Y., additional, Pritchard, Susan, additional, Langer, Rupert, additional, Stenning, Sally Patricia, additional, and Cunningham, David, additional

Published
2015
Full Text
View/download PDF

89. Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061).

Author

Mulvenna, Paula Mary, primary, Nankivell, Matthew Guy, additional, Barton, Rachael, additional, Faivre-Finn, Corinne, additional, Wilson, Paula, additional, Moore, Barbara, additional, McColl, Elaine, additional, Brisbane, Iona, additional, Ardron, David, additional, Sydes, Benjamin, additional, Pugh, Cheryl, additional, Holt, Tanya, additional, Bayman, Neil, additional, Morgan, Sally, additional, Lee, Caroline, additional, Waite, Kathryn, additional, Stephens, Richard, additional, Parmar, Mahesh M K, additional, and Langley, Ruth E, additional

Published
2015
Full Text
View/download PDF

90. Oestrogen patches (OP) to treat prostate cancer (PC) – Are different commercial brands interchangeable?

Author

Langley, Ruth E., primary, Duong, Trinh, additional, Godsland, Ian F., additional, Kynaston, Howard, additional, Kockelbergh, Roger, additional, Rosen, Stuart D., additional, Alhasso, Abdulla A., additional, Dearnaley, David P., additional, Clarke, Noel W., additional, Jovic, Gordana, additional, Carpenter, Robin, additional, Bara, Anna, additional, Welland, Andrew, additional, Parmar, Mahesh K., additional, and Abel, Paul D., additional

Published
2015
Full Text
View/download PDF

91. Effect of TP53 mutation status on survival in the MAGIC trial.

Author

Smyth, Elizabeth Catherine, primary, Hulkki Wilson, Sanna, additional, Nankivell, Matthew Guy, additional, Gonzalez de Castro, David, additional, Wotherspoon, Andrew, additional, Okines, Alicia Frances Clare, additional, Langley, Ruth E, additional, Stenning, Sally Patricia, additional, and Cunningham, David, additional

Published
2015
Full Text
View/download PDF

93. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones ( PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.

Author

Gilbert, Duncan C., Duong, Trinh, Kynaston, Howard G., Alhasso, Abdulla A., Cafferty, Fay H., Rosen, Stuart D., Kanaga‐Sundaram, Subramanian, Dixit, Sanjay, Laniado, Marc, Madaan, Sanjeev, Collins, Gerald, Pope, Alvan, Welland, Andrew, Nankivell, Matthew, Wassersug, Richard, Parmar, Mahesh K. B., Langley, Ruth E., and Abel, Paul D.

Subjects
PROSTATE cancer treatment, QUALITY of life, ADENOCARCINOMA, CANCER hormone therapy, ESTRADIOL
Abstract

Objectives To compare quality-of-life (QoL) outcomes at 6 months between men with advanced prostate cancer receiving either transdermal oestradiol ( tE2) or luteinising hormone-releasing hormone agonists ( LHRHa) for androgen-deprivation therapy ( ADT). Patients and methods Men with locally advanced or metastatic prostate cancer participating in an ongoing randomised, multicentre UK trial comparing tE2 versus LHRHa for ADT were enrolled into a QoL sub-study. tE2 was delivered via three or four transcutaneous patches containing oestradiol 100 μg/24 h. LHRHa was administered as per local practice. Patients completed questionnaires based on the European Organisation for Research and Treatment of Cancer quality of life questionnaire 30-item core ( EORTC QLQ-C30) with prostate-specific module QLQ PR25. The primary outcome measure was global QoL score at 6 months, compared between randomised arms. Results In all, 727 men were enrolled between August 2007 and October 2015 (412 tE2, 315 LHRHa) with QoL questionnaires completed at both baseline and 6 months. Baseline clinical characteristics were similar between arms: median (interquartile range) age of 74 (68-79) years and PSA level of 44 (19-119) ng/mL, and 40% (294/727) had metastatic disease. At 6 months, patients on tE2 reported higher global QoL than those on LHRHa (mean difference +4.2, 95% confidence interval 1.2-7.1; P = 0.006), less fatigue, and improved physical function. Men in the tE2 arm were less likely to experience hot flushes (8% vs 46%), and report a lack of sexual interest (59% vs 74%) and sexual activity, but had higher rates of significant gynaecomastia (37% vs 5%). The higher incidence of hot flushes among LHRHa patients appear to account for both the reduced global QoL and increased fatigue in the LHRHa arm compared to the tE2 arm. Conclusion Patients receiving tE2 for ADT had better 6-month self-reported QoL outcomes compared to those on LHRHa, but increased likelihood of gynaecomastia. The ongoing trial will evaluate clinical efficacy and longer term QoL. These findings are also potentially relevant for short-term neoadjuvant ADT. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

96. Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors.

Author

Langley, Ruth E, primary, Wilson, Richard H., additional, Ring, Alistair E., additional, Kynaston, Howard Gordon, additional, Cameron, David A., additional, Coyle, Christopher, additional, Gilbert, Duncan Charles, additional, Patrono, Carlo, additional, Rowley, Sam, additional, Murphy, Claire, additional, Adlam, David, additional, Hubner, Richard, additional, Iveson, Tim, additional, Steele, Robert J, additional, Thomas, Anne L., additional, Underwood, Timothy J, additional, Jankowski, Janusz, additional, Gupta, Sudeep, additional, Pramesh, Conjeevaram S, additional, and Parmar, Mahesh, additional

Published
2014
Full Text
View/download PDF

97. Prostate Adenocarcinoma: TransCutaneous Hormones, PR09 (PATCH): A randomized controlled trial of transdermal estrogen patches versus luteinising hormone releasing hormone agonists in locally advanced and metastatic prostate cancer.

Author

Langley, Ruth E, primary, Duong, Trinh, additional, Jovic, Gordana, additional, Alhasso, Abdulla A, additional, Kynaston, Howard, additional, Dearnaley, David Paul, additional, Rosen, Stuart D, additional, Kockelbergh, Roger, additional, Clarke, Noel W., additional, Godsland, Ian F, additional, Sundaram, Subramanian K, additional, Dixit, Sanjay, additional, Laniado, Marc, additional, Stockdale, Andrew, additional, Pope, Alvan, additional, Paez, Edgar M, additional, Spittle, Ben, additional, Bara, Anna, additional, Parmar, Mahesh M K, additional, and Abel, Paul D, additional

Published
2014
Full Text
View/download PDF

98. Bone density in men receiving androgen deprivation therapy for prostate cancer: A randomized comparison between transdermal estrogen and luteinising hormone-releasing hormone agonists.

Author

Langley, Ruth E, primary, Duong, Trinh, additional, Jovic, Gordana, additional, Cafferty, Fay, additional, Honeyfield, Lesley, additional, Abel, Richard, additional, Stone, Michael, additional, Kynaston, Howard, additional, Alhasso, Abdulla A, additional, Scrase, Christopher D, additional, Paez, Edgar M, additional, Spittle, Ben, additional, Bara, Anna, additional, Parmar, Mahesh M K, additional, and Abel, Paul D, additional

Published
2014
Full Text
View/download PDF

99. MAGIC germline polymorphism analysis.

Author

Smyth, Elizabeth Catherine, primary, Zhang, Shenli, additional, Cunningham, David, additional, Tan, Iain B., additional, Wotherspoon, Andrew, additional, Soong, Richie, additional, Sapari, Nur Sabrina Binte, additional, Okines, Alicia Frances Clare, additional, Langley, Ruth E., additional, Stenning, Sally Patricia, additional, Nankivell, Matthew Guy, additional, and Tan, Patrick, additional

Published
2014
Full Text
View/download PDF

100. The relationship between tumor cell density in the pretreatment biopsy and survival after chemotherapy in OE02 trial esophageal cancer patients.

Author

Hale, Matthew D., primary, Nankivell, Matthew Guy, additional, Mueller, Wolfram, additional, West, Nicholas P., additional, Stenning, Sally Patricia, additional, Wright, Alexander I., additional, Treanor, Darren, additional, Langley, Ruth E., additional, Ward, Lindsay C., additional, Allum, William H., additional, Cunningham, David, additional, Hayden, Jeremy D., additional, and Grabsch, Heike I., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results